Isolation of a panel of ultra-potent human antibodies neutralizing SARS-CoV-2 and viral variants of concern

Andrey A. Gorchakov, Sergey V. Kulemzin, Sergey V. Guselnikov, Konstantin O. Baranov, Tatyana N. Belovezhets, Ludmila V. Mechetina, Olga Yu Volkova, Alexander M. Najakshin, Nikolai A. Chikaev, Anton N. Chikaev, Pavel P. Solodkov, Victor F. Larichev, Marina A. Gulyaeva, Alexander G. Markhaev, Yulia V. Kononova, Alexander Yu Alekseyev, Alexander M. Shestopalov, Gaukhar M. Yusubalieva, Tatiana V. Klypa, Alexander V. IvanovVladimir T. Valuev-Elliston, Vladimir P. Baklaushev, Alexander V. Taranin

Результат исследования: Научные публикации в периодических изданияхстатьярецензирование


In the absence of virus-targeting small-molecule drugs approved for the treatment and prevention of COVID-19, broadening the repertoire of potent SARS-CoV-2-neutralizing antibodies represents an important area of research in response to the ongoing pandemic. Systematic analysis of such antibodies and their combinations can be particularly instrumental for identification of candidates that may prove resistant to the emerging viral escape variants. Here, we isolated a panel of 23 RBD-specific human monoclonal antibodies from the B cells of convalescent patients. A surprisingly large proportion of such antibodies displayed potent virus-neutralizing activity both in vitro and in vivo. Four of the isolated nAbs can be categorized as ultrapotent with an apparent IC100 below 16 ng/mL. We show that individual nAbs as well as dual combinations thereof retain activity against currently circulating SARS-CoV-2 variants of concern (such as B.1.1.7, B.1.351, B.1.617, and C.37), as well as against other viral variants. When used as a prophylactics or therapeutics, these nAbs could potently suppress viral replication and prevent lung pathology in SARS-CoV-2-infected hamsters. Our data contribute to the rational development of oligoclonal therapeutic nAb cocktails mitigating the risk of SARS-CoV-2 escape.

Язык оригиналаанглийский
Номер статьи96
ЖурналCell Discovery
Номер выпуска1
СостояниеОпубликовано - дек 2021

Предметные области OECD FOS+WOS



Подробные сведения о темах исследования «Isolation of a panel of ultra-potent human antibodies neutralizing SARS-CoV-2 and viral variants of concern». Вместе они формируют уникальный семантический отпечаток (fingerprint).